- Home
- ERAS vs HUMA Comparison
ERAS vs HUMA Comparison
Compare ERAS & HUMA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ERAS
- HUMA
- Stock Information
- Founded
- ERAS 2018
- HUMA 2004
- Country
- ERAS United States
- HUMA United States
- Employees
- ERAS N/A
- HUMA N/A
- Industry
- ERAS Biotechnology: Pharmaceutical Preparations
- HUMA Biotechnology: Pharmaceutical Preparations
- Sector
- ERAS Health Care
- HUMA Health Care
- Exchange
- ERAS Nasdaq
- HUMA Nasdaq
- Market Cap
- ERAS 432.6M
- HUMA 427.2M
- IPO Year
- ERAS 2021
- HUMA N/A
- Fundamental
- Price
- ERAS $1.16
- HUMA $1.68
- Analyst Decision
- ERAS Strong Buy
- HUMA Strong Buy
- Analyst Count
- ERAS 6
- HUMA 6
- Target Price
- ERAS $4.83
- HUMA $14.60
- AVG Volume (30 Days)
- ERAS 2.3M
- HUMA 6.6M
- Earning Date
- ERAS 05-07-2025
- HUMA 05-09-2025
- Dividend Yield
- ERAS N/A
- HUMA N/A
- EPS Growth
- ERAS N/A
- HUMA N/A
- EPS
- ERAS N/A
- HUMA N/A
- Revenue
- ERAS N/A
- HUMA N/A
- Revenue This Year
- ERAS N/A
- HUMA N/A
- Revenue Next Year
- ERAS N/A
- HUMA $1,178.15
- P/E Ratio
- ERAS N/A
- HUMA N/A
- Revenue Growth
- ERAS N/A
- HUMA N/A
- 52 Week Low
- ERAS $1.01
- HUMA $1.15
- 52 Week High
- ERAS $3.45
- HUMA $9.97
- Technical
- Relative Strength Index (RSI)
- ERAS 41.47
- HUMA 38.93
- Support Level
- ERAS $1.01
- HUMA $1.43
- Resistance Level
- ERAS $1.29
- HUMA $1.62
- Average True Range (ATR)
- ERAS 0.17
- HUMA 0.18
- MACD
- ERAS 0.00
- HUMA 0.07
- Stochastic Oscillator
- ERAS 31.25
- HUMA 70.67
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.
About HUMA Humacyte Inc.
Humacyte Inc is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. It develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions.